PTO/SB/30 (03-09)

Approved for use through 04/30/2009, OMB 0851-0031 U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE Under the Pagework Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.					
Request		Application Number	10/711,699		
for		Filing Date	September	September 30, 2004	
Continued Examination (RCE) Transmittal		First Named Inventor	. Gueorgui M	omtchilov	
Address to:		Art Unit	2451		
Mail Stop RCE Commissioner for Patents		Examiner Name	Matthew S.	Lindsey	
P.O. Box 1450 Alexandria, VA 22313-1450		Attorney Docket Nun	ther 2006579-03	15 (CTX-102)	
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.					
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utilify or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.					
 Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). 					
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.					
Consider the arguments in the Appeal Brief or Reply Brief previously filed on Other					
b. 🗸 Enclosed					
ı. 🔽	Amendment/Reply	iji. Infor	mation Disclosure S	Statement (IDS)	
ii.	Affidavit(s)/ Declaration(s)	iv. Othe	er		
2. Miscellaneous					
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a. period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)					
	ther			7(() toquirou)	
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is hereby authorized to change the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 03-1721.					
i. RCE fee required under 37 CFR 1.17(e)					
II. Extension of time fee (37 CFR 1.136 and 1.17)					
ill. Other					
b. Check in the amount of \$enclosed					
c. Payment by credit card (Form PTO-2038 enclosed)					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Signature Name (Print/Type)	/Kellan D. Ponikiewicz/		Date Registration No.	June 4, 2009	
Name (Fillio Type)	Kellan D. Ponikiewicz			59,701	
I hereby certify that this correspondence is being deposited with the United States Pectal Service with undictival postage as first class mail in an envelope addressed to Mail Stop RCE. Commissioner for Patients, P. O. Box 1450, Alexandris, VA 22313-1450 or facultmile transmitted to the U.S. Pettent and Trademark Office on the date shown below.					
Signature					
Name (Print/Type) This collection of infor	metion is required by 37 CFR 1.114. The informat	ion is required to obtain or retain	Date a benefit by the publi	c which is to file (and by the USPTO	
to process) an applice	tion Confidentiality is poverned by 35 U.S.C. 122	and 37 CFR 1.11 and 1.14. T	his collection is estima	ted to take 12 minutes to complete.	

This collection of Information is required by 3°C ER 1.114. The information is required to detain or retain a benefit by the public which is to life (and by the USFTO to process) are publication. Confidentially is governed by 30°C ER 1.114. The information is required to detain or retain a benefit by the public which is to life (and by the USFTO to process) are confidentially estimated to later 2 minutes to complete the series of the confidential to the confidential to the confidential to the confidential to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commence, P.O. Box 4160, Alexandria, VA 2231-4450. DNO TS SEN PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO TS SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 2231-4450. DNO SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: MAIL THE PATENT TO THE PATENT THE PA

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandomment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy, Act (6 U.S. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A fecord in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, by whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipitents of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 5524(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.